Clinical trials: West Nile Virus
West Nile Virus
A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults
The primary purpose of this phase 1, double-blind, cohort study is to evaluate the safety, tolerability, and pharmacokinetics of escalating doses of MGAWN1 administered as a single intravenous (IV) infusion to healthy adults.
- Trial name
- NCT00515385
- Testing
- MGAWN1
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- MacroGenics
West Nile Fever
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4delta30) in Healthy Adults
West Nile (WN) virus infection is an emerging disease. Infection with WN virus may lead to paralysis, coma, and death. The purpose of this study is to determine the safety of and immune response to a two-dose regimen of a WN…
- Trial name
- NCT00537147
- Testing
- WN/DEN4delta30 vaccine
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
West Nile Virus
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
During a clinical study of people with severe West Nile virus infections, it was determined that the drug AVI-4020 crossed the blood-brain barrier.
- Trial name
- NCT00387283
- Testing
- AVI-4020 Injection
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Sarepta Therapeutics, Inc.
Healthy, West Nile Fever
Vaccine to Prevent West Nile Virus Disease
This study will test the safety of an experimental vaccine intended to prevent West Nile virus (WNV) infection and determine if it causes side effects.
- Conditions
- Healthy, West Nile Fever, Healthy Volunteer, HV
- Trial name
- NCT00106769
- Testing
- VRC-WNVDNA017-00-VP
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
West Nile Fever
Phase I Study of West Nile Virus Vaccine
This study will test the safety of an experimental vaccine for preventing West Nile virus infection. The virus is spread mainly by mosquito bites.
- Trial name
- NCT00300417
- Testing
- VRC-WNVDNA020-00-VP
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
West Nile Fever Encephalitis
Safety of and Immune Response to a West Nile Virus Vaccine (WN/DEN4-3'delta30) in Healthy Adults
West Nile (WN) virus infection is an emerging disease; WN infection may lead to paralysis, coma, and death. The purpose of this study is to test the safety of and immune response to a WN vaccine in healthy adults.
- Trial name
- NCT00094718
- Testing
- WN/DEN4-3'delta30
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
West Nile Viral Infection
Phase 1 Trial of Inactivated West Nile Virus Vaccine
This trial will be a randomized, placebo controlled, double-blind (within dosing group), dose escalation phase 1 trial, evaluating dosages of 1 mcg and 4 mcg of HydroVax-001 WNV vaccine given intramuscularly on Day 1 and Day 29…
- Trial name
- NCT02337868
- Testing
- HydroVax-001
- Where
- United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
West Nile Fever
Safety and Immunogenicity Study of ChimeriVax West Nile Vaccine in Healthy Adults
The purpose of this study is to determine if ChimeriVax West Nile vaccine is safe and effective in preventing West Nile disease in adults over 50 years of age.
- Trial name
- WinVax004 (NCT00746798)
- Testing
- ChimeriVax-WN02 vaccine
- Where
- 15 sites in United States
- Volunteers
- 479 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
West Nile Viral Infection
Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults
A randomized, placebo controlled, double-blind (within dosing group), sequential dose escalation study. This phase 1 trial addresses the urgent need for a vaccine to prevent disease resulting from infection with West Nile virus…
- Trial name
- NCT06745921
- Testing
- HydroVax-001B WNV, Sodium Chloride, 0.9%
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
West Nile Virus
Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age
West Nile virus (WNV) is considered an emerging virus in the United States, and infection can lead to severe illness in older adults.
- Trial name
- NCT02186626
- Testing
- WN/DEN4Δ30 Vaccine
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
West Nile Virus
West Nile Virus Seroprevalence Under Bird Ringers
In August 2020, West Nile Virus (WNV) was isolated from a live common whitethroat for the first time in The Netherlands. Follow-up sampling showed that the virus could also be detected in mosquitos from the same location during…
- Trial name
- NCT05294003
- Where
- Netherlands
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
West Nile Virus, West Nile Fever
Prospective Investigation of Oxidative Stress in West Nile Virus Infection
The investigator hypothesizes that oxidative stress responses to West Nile virus infection in the central nervous system determine the severity of infection and the long-term neurological, neuropsychological and functional…
- Conditions
- West Nile Virus, West Nile Fever, West Nile Fever Encephalitis, West Nile Fever Meningitis
- Trial name
- PROWENI (NCT04371003)
- Where
- Romania
- Volunteers
- healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
West Nile Fever
Safety and Immunogenicity of ChimeriVax-WN02 West Nile Vaccine in Healthy Adults
The purpose of this study is to determine whether a single subcutaneous injection of ChimeriVax-WN02 vaccine is well tolerated, safe and induces protective antibodies against West Nile Disease.
- Trial name
- NCT00442169
- Testing
- ChimeriVax-WN02 Low Dose, ChimeriVax-WN02 Medium Dose, ChimeriVax-WN02 High Dose
- Where
- 5 sites in United States
- Volunteers
- 208 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
West Nile Virus Disease
Safety Study of HBV-002 West Nile Vaccine in Healthy Adults
The purpose of this Phase 1 trial is to evaluate the clinical safety of HBV-002 vaccine in healthy adults.
- Trial name
- NCT00707642
- Testing
- WN-80E
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Hawaii Biotech, Inc.